Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus

Virology

Volumn 385, Issue 2, 2009, Pages 409-415

  Näslund, Jonas ^a,b   Lagerqvist, Nina ^a,b,c   Habjan, Matthias ^d   Lundkvist, Åke ^c   Evander, Magnus ^b   Ahlm, Clas ^b   Weber, Friedemann ^d   Bucht, Göran ^a,e  

^a SWEDISH DEFENCE RESEARCH AGENCY   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^d UNIVERSITY OF FREIBURG   (Germany)

^e NATIONAL ENVIRONMENT AGENCY   (Singapore)

Author keywords

Challenge; Mouse model; Rift Valley Fever; Vaccine; Virus like particle

Indexed keywords

MYXOVIRUS RESISTANCE PROTEIN A; NEUTRALIZING ANTIBODY; NUCLEOCAPSID PROTEIN; RIFT VALLEY FEVER BUNYAVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS RNA; VIRUS VACCINE;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCING CELL; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL INFECTION; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; LOW DRUG DOSE; MAMMAL CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RIFT VALLEY FEVER BUNYAVIRUS; RNA VIRUS INFECTION; SEROCONVERSION; SURVIVAL; VACCINATION; VIRUS LIKE AGENT; VIRUS REPLICATION; VIRUS TITRATION; VIRUS TRANSCRIPTION;

ANIMALS; CERCOPITHECUS AETHIOPS; FEMALE; MICE; MICE, INBRED C57BL; NEUTRALIZATION TESTS; NUCLEOCAPSID PROTEINS; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; SURVIVAL ANALYSIS; VACCINATION; VERO CELLS; VIRAL VACCINES; VIRION; VIRUS REPLICATION;

ANIMALIA; MAMMALIA; MUS; ORTHOBUNYAVIRUS; RIFT VALLEY FEVER VIRUS;

EID: 60649088296     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.12.012     Document Type: Article

References (51)

1. Al-Hazmi M., Ayoola E.A., Abdurahman M., Banzal S., Ashraf J., El-Bushra A., Hazmi A., Abdullah M., Abbo H., Elamin A., Al-Sammani el.-T., Gadour M., Menon C., Hamza M., Rahim I., Hafez M., Jambavalikar M., Arishi H., and Aqeel A. Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans. Clin. Infect. Dis. 36 (2003) 245-252
2. André F., and Safary A. Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine. Postgrad. Med. J. 63 Suppl 2 (1987) 169-177
3. Balkhy H., and Memish Z. Rift Valley fever: an uninvited zoonosis in the Arabian peninsula. Int. J. Antimicrob. Agents 21 (2003) 153-157
4. Bertolotti-Ciarlet A., Ciarlet M., Crawford S., Conner M., and Estes M. Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine 21 (2003) 3885-3900
5. Billecocq A., Spiegel M., Vialat P., Kohl A., Weber F., Bouloy M., and Haller O. NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription. J. Virol. 78 (2004) 9798-9806
6. Billecocq A., Gauliard N., Le May N., Elliott R., Flick R., and Bouloy M. RNA polymerase I-mediated expression of viral RNA for the rescue of infectious virulent and avirulent Rift Valley fever viruses. Virology 378 (2008) 377-384
7. Bird B., Albariño C., Hartman A., Erickson B., Ksiazek T., and Nichol S. Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J. Virol. 82 (2008) 2681-2691
8. Botros B., Omar A., Elian K., Mohamed G., Soliman A., Salib A., Salman D., Saad M., and Earhart K. Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J. Med. Virol. 78 (2006) 787-791
9. Caplen H., Peters C.J., and Bishop D. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J. Gen. Virol. 66 (1985) 2217-2271
10. Coetzer J., and Barnard B. Hydrops amnii in sheep associated with hydranencephaly and arthrogryposis with wesselsbron disease and rift valley fever viruses as aetiological agents. Onderstepoort J. Vet. Res. 44 (1977) 119-126
11. Crawford S., Labbé M., Cohen J., Burroughs M., Zhou Y., and Estes M. Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. J. Virol. 68 (1994) 5945-5952
12. Elliott R. In: Frankel-Conrat H., and Wagner R.R. (Eds). "The Bunyaviridae." The Viruses (1996), Plenum Press, New York
13. Flick R., and Bouloy M. Rift Valley fever virus. Curr. Mol. Med. 5 (2005) 827-834
14. Gerdes G. Rift Valley fever. Rev. Sci. Tech. 23 (2004) 613-623
15. Gerrard S., Bird B., Albariño C., and Nichol S. The NSm proteins of Rift Valley fever virus are dispensable for maturation, replication and infection. Virology 359 (2007) 459-465
16. Grgacic E., and Anderson D. Virus-like particles: passport to immune recognition. Methods 40 (2006) 60-65
17. Habjan M., Penski N., Spiegel M., and Weber F. T7 RNA polymerase-dependent and -independent systems for cDNA-based rescue of Rift Valley fever virus. J. Gen. Virol. 89 (2008) 2157-2166
18. Habjan M., Penski N., Wagner V., Spiegel M., Överby A.K., Kochs G., Huiskonen J., and Weber F. Efficient production of Rift Valley fever virus-like particles: the antiviral protein MxA can inhibit primary transcription of Bunyaviruses. Virology 385 (2009) 400-408
19. Harper D., Franco E., Wheeler C., Moscicki A., Romanowski B., Roteli-Martins C., Jenkins D., Schuind A., Costa Clemens S., and Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
20. Hunter P., Erasmus B., and Vorster J. Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. Onderstepoort J. Vet. Res. 69 (2002) 95-98
21. Ikegami T., Won S., Peters C.J., and Makino S. Rescue of infectious rift valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene. J. Virol. 80 (2006) 2933-2940
22. Jansen van Vuren P., Potgieter A., Paweska J., and van Dijk A. Preparation and evaluation of a recombinant Rift Valley fever virus N protein for the detection of IgG and IgM antibodies in humans and animals by indirect ELISA. J. Virol. Methods 140 (2007) 106-114
23. Kark J., Aynor Y., and Peters C.J. A Rift Valley fever vaccine trial. I. Side effects and serologic response over a six-month follow-up. Am. J. Epidemiol. 116 (1982) 808-820
24. Kirnbauer R., Booy F., Cheng N., Lowy D., and Schiller J. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 12180-12184
25. Latham T., and Galarza J. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J. Virol. 75 (2001) 6154-6165
26. Le May N., Dubaele S., Proietti De Santis L., Billecocq A., Bouloy M., and Egly J. TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus. Cell 116 (2004) 541-550
27. Le May N., Gauliard N., Billecocq A., and Bouloy M. The N terminus of Rift Valley fever virus nucleoprotein is essential for dimerization. J. Virol. 79 (2005) 11974-11980
28. Lindkvist M., Lahti K., Lilliehöök B., Holmström A., Ahlm C., and Bucht G. Cross-reactive immune responses in mice after genetic vaccination with cDNA encoding hantavirus nucleocapsid proteins. Vaccine 25 (2007) 1690-1699
29. Lubroth J., Rweyemamu M., Viljoen G., Diallo A., Dungu B., and Amanfu W. Veterinary vaccines and their use in developing countries. Rev. Sci. Tech. 26 (2007) 179-201
30. Mao C., Koutsky L., Ault K., Wheeler C., Brown D., Wiley D., Alvarez F., Bautista O., Jansen K., and Barr E. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol. 107 (2006) 18-27
31. McAleer W., Buynak E., Maigetter R., Wampler D., Miller W., and Hilleman M. Human hepatitis B vaccine from recombinant yeast. Nature 307 (1984) 178-180
32. Meegan J. The Rift Valley fever epizootic in Egypt 1977-78. 1. Description of the epizootic and virological studies. Trans. R. Soc. Trop. Med. Hyg. 73 (1979) 618-623
33. Metwally S. In: Brown C., and Torres A. (Eds). Foreign Animal Diseases. 7th ed (2008), Boca Publications Group, Inc., Boca Raton, FL 369-376
34. Morrill J.C., Mebus C.A., and Peters C.J. Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am J Vet Res. 58 10 (1997) 1104-1109 PMID: 9328662
35. Muller R., Saluzzo J., Lopez N., Dreier T., Turell M., Smith J., and Bouloy M. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am. J. Trop. Med. Hyg. 53 (1995) 405-411
36. Näslund J., Lagerqvist N., Lundkvist Å., Evander M., Ahlm C., and Bucht G. Kinetics of Rift Valley Fever Virus in experimentally infected mice using quantitative real-time RT-PCR. J. Virol. Methods 151 (2008) 277-282
37. Pittman P., Liu C., Cannon T., Makuch R., Mangiafico J., Gibbs P., and Peters C.J. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine 18 (1999) 181-189
38. Pushko P., Tumpey T., Bu F., Knell J., Robinson R., and Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 23 (2005) 5751-5759
39. Reading S., and Dimmock N. Neutralization of animal virus infectivity by antibody. Arch. Virol. 152 (2007) 1047-1059
40. Sall A., Zanotto P., Sene O., Zeller H., Digoutte J., Thiongane Y., and Bouloy M. Genetic reassortment of Rift Valley fever virus in nature. J. Virol. 73 (1999) 8196-8200
41. Siam A., Meegan J., and Gharbawi K. Rift Valley fever ocular manifestations: observations during the 1977 epidemic in Egypt. Br. J. Ophthalmol. 64 (1980) 366-374
42. Smithburn K.C. Rift Valley Fever: the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br. J. Exp. Pathol. 1 (1949) 1-16
43. Swenson D., Warfield K., Negley D., Schmaljohn A., Aman M., and Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 23 (2005) 3033-3042
44. van Oirschot J. Diva vaccines that reduce virus transmission. J. Biotechnol. 73 (1999) 195-205
45. Vialat P., Muller R., Vu T., Prehaud C., and Bouloy M. Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation. Virus Res. 52 (1997) 43-50
46. Vieira H., Estêvão C., Roldão A., Peixoto C., Sousa M., Cruz P., Carrondo M., and Alves P. Triple layered rotavirus VLP production: kinetics of vector replication, mRNA stability and recombinant protein production. J. Biotechnol. 120 (2005) 72-82
47. Villa L., Costa R., Petta C., Andrade R., Ault K., Giuliano A., Wheeler C., Koutsky L., Malm C., Lehtinen M., Skjeldestad F., Olsson S., Steinwall M., Brown D., Kurman R., Ronnett B., Stoler M., Ferenczy A., Harper D., Tamms G., Yu J., Lupinacci L., Railkar R., Taddeo F., Jansen K., Esser M., Sings H., Saah A., and Barr E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6 (2005) 271-278
48. Warfield K., Swenson D., Negley D., Schmaljohn A., Aman M., and Bavari S. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine 22 (2004) 3495-3502
49. Won S., Ikegami T., Peters C.J., and Makino S. NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. J. Virol. 81 (2007) 13335-13345
50. Zaki A., Coudrier D., Yousef A., Fakeeh M., Bouloy M., and Billecocq A. Production of monoclonal antibodies against Rift Valley fever virus Application for rapid diagnosis tests (virus detection and ELISA) in human sera. J. Virol. Methods 131 (2006) 34-40
51. Zhou J., Sun X., Stenzel D., and Frazer I. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185 (1991) 251-257